This article first appeared on GuruFocus.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Herbalife Ltd (NYSE:HLF) delivered its fourth consecutive quarter of year-over-year net sales growth, with Q2 net sales up 5.4% reported and 5.8% on a constant currency basis, exceeding guidance.
The company saw strong performance in key regions, with India posting a 47% constant currency net sales increase and Latin America delivering its fourth consecutive quarter of double-digit growth.
Herbalife Ltd (NYSE:HLF) is expanding its personalized nutrition portfolio with new product launches like Bionic Go and Life IO, positioning itself in high-growth markets such as AI-powered nutrition and longevity.
The company generated robust cash flow, with first-half operating cash flow up 52% year-over-year, and reduced net interest expense to $37 million from $54 million in the prior year.
Herbalife Ltd (NYSE:HLF) successfully refinanced its debt in April, reducing leverage and lowering borrowing costs, while maintaining a strong free cash flow yield of over 23%.
The company is investing in technology, including the Protocol platform and blood testing beta, to enhance distributor capabilities and customer engagement, which could drive future growth.
Herbalife Ltd (NYSE:HLF) reported a GAAP net loss of $26 million in Q2, primarily due to a $95 million pre-tax loss on debt extinguishment from the April refinancing.
The company faces ongoing foreign exchange headwinds, with FX negatively impacting net sales by 40 basis points in Q2 and expected to be a 100 basis point headwind in Q3.
China, the company's smallest region, saw a significant decline, with reported net sales down 25% and constant currency net sales down 29% due to a 29% volume decrease.
EMEA region experienced a decline in net sales, with reported sales down 3.5% and constant currency sales down 5.6%, driven by a 12% volume drop.
Gross profit margin decreased by 30 basis points year-over-year, impacted by unfavorable country mix, higher other costs, and increased inventory reserves.
The adjusted effective tax rate rose to 43.2% in Q2 from 27.7% in the prior year, negatively impacting adjusted diluted EPS by approximately $0.14.
Warning! GuruFocus has detected 3 Warning Signs with HLF.
Is HLF fairly valued? Test your thesis with our free DCF calculator.
Q: How do you ensure stronger distributor retention in Asia Pacific, particularly in India, during and after this rapid growth phase? A: Stefan Graziani (CEO) explained that the growth is driven by strong business models and customer support systems put in place by distributor leadership. A price adjustment made products more accessible, and distributors have effectively managed the influx of customers through their systems and clubs. John De Simone (CFO) added that India has had 18 straight years of growth, demonstrating their ability to build discipline underneath growth, which gives confidence in managing this current expansion.
Q: Are individual distributors performing better in North America, given that net sales per distributor is up year-over-year and active sales leaders grew from Q1 to Q2? A: Stefan Graziani (CEO) confirmed that the takeaway is accurate. He noted increased productivity among distributors in North America, with an even greater change in productivity for new distributors compared to traditional run rates. He highlighted that nutrition club productivity is up, which is an important indicator of the health of the business in the region.
Q: What have you seen from distributors since the launch of the new Life IO products, and how have they reached a more sophisticated consumer? A: Stefan Graziani (CEO) deferred this question, stating that the products were launched in July (Q3) and it was too early to provide figures. He acknowledged there was lots of excitement at the launch event but suggested waiting until the next quarterly call to discuss performance data.
Q: What is driving the narrowing and modest reduction of the CapEx range for the year? A: John De Simone (CFO) explained that the company has a disciplined approach to reviewing capital expenditure projects, requiring ROI analysis before approval. The underspend is due to reprioritizing and delaying some projects, not financial constraints. He emphasized that the company generates plenty of cash and is investing in projects that add value.
Q: With protein becoming ubiquitous in the grocery aisle, does this competitive environment help or hurt Herbalife's distributors? A: Stefan Graziani (CEO) stated that it is a good thing, as it validates what Herbalife has been doing for over 45 years. He noted that the company is looking closely at its protein offerings to grab more market share and extend its lead. He believes increased consumer awareness is a positive and expands the overall market.
Q: Can you talk about expected cost or inflation pressures for next year, particularly regarding input costs like whey? A: John De Simone (CFO) acknowledged seeing some pressure on input costs, with whey being one of the bigger increases, though it is not the dominant protein type sold. He also mentioned pressure from packaging and freight due to oil prices. He stated the impact is manageable and expects to recover these costs through normal price increase structures next year.
Q: With a new CFO coming in, are there any potential changes to your leverage target or thoughts on capital allocation? A: John De Simone (CFO) confirmed there are no changes at this time. He reiterated that the priority remains reducing debt, and he made this clear on the call so investors know the policy hasn't changed. He noted that capital allocation is a board-level decision, and Scott Shaffer, the incoming CFO, will not be a driver of change unless circumstances change.
Q: Does the recent M&A news of P&G buying a premium supplement company (Thorne) change your thinking on how to go to market or the competitive environment? A: Stefan Graziani (CEO) viewed the deal as validation of the company's strategy and the capabilities they are bringing to market. He noted it confirms the direction of the personalized nutrition market and that the Life IO brand is designed to target that audience. He sees it as a natural progression for the company.
Q: What has the reaction been among distributors to the beta test of the blood biomarker diagnostics introduced at the extravaganza? A: Stefan Graziani (CEO) described the beta launch as an opportunity to enter the blood-based testing and biomarker segment of personalized nutrition. He explained they are validating the end-to-end experience, from ordering and self-administering the test to lab processing and delivering results through the Protocol platform. He emphasized this is the beginning of a process and part of the "what to measure" element of their strategy.
Q: What is next in the personalized nutrition space following the rollout of Bionic Go in Europe and North America? A: Stefan Graziani (CEO) stated that additional market launches are planned for the end of the year. He confirmed that Bionic Go is the first product in the line for this category and that there will be more to come, though the company is not ready to discuss specifics at this time.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.